Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Investors are seeking only one thing: a sign the pandemic tide is shifting

In 2Q20, all eyes are on COVID-19 catalysts that could stabilize the market

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market.

On the other hand, the virtual technologies taking root all over might help some companies soften the blow as they explore virtual launches while their sales forces are grounded.

“The biggest event for our sector right now is how the paths play out around this pandemic,” Deerfield’s Alex Karnal told BioCentury. “When you end up in a world where securities are highly correlated, idiosyncratic single company events have the potential to be less meaningful to your performance than what might happen across the sector in a short period of time.”

In any other scenario, the second quarter of 2020 would have been ripe with a plethora of catalysts: cancer data at American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO), numerous PDUFA dates, and likely the biggest of them all, news on

Read the full 1656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE